Great Novel Therapeutics Biotech & Medicals Corporation

Gnt Biotech & Medicals Corporation

Ye-Su Chao

Chia-Nan Chen

Yi-Hong Wu

Jia-Shiong Chen

Cheng-Han Chou

Mu-Hsuan Yang

Sz-Hao Chu

Wei-Jan Huang

Li-Ling Chi

Ching-Yi Lin

Meng-Ju Tsai

Yu-Jung Liao

Huan-Yu Lin

Wan-Yi Hsu

Ching-yi Lin

The present disclosure generally relates to compounds class I HDAC inhibitors, their production and applications. The compounds possess epigenetic immunomodulatory activities in the tumor microenvironment (TME) and thus inhibit growth of tumor cells.

Histone deacetylase inhibitors for immunomodulation in tumor microenvironment

The present invention relates to a combination of a histone deacetylase (HDAC) inhibitor, chidamide in an acidic salt form, and a nonsteroidal anti-inflammatory drugs (NSAIDs), celecoxib in a basic salt form. The present invention also relates to methods which significantly regulate tumor microenvironment and therefore dramatically improve anti-cancer activity.

Anticancer combination of chidamide and celecoxib salts

The invention relates to a method of removing immune suppression in a tumor microenvironment or stimulating an immune system against cancer cells, comprising administering to a subject a combination of a HDAC inhibitor and an NSAID in combination with an immune checkpoint inhibitor.

Pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy

The invention provides a pH-sensitive linker that can simultaneously bind metallic nanoparticles and one or more agents with various molecular size. The linker of the invention can deliver the agents into cells involved in disease processes or close to cells so that the agents can selectively target and effect on the cells. The target delivery provided by the linker of the invention can be used for example for disease sensing, imaging, drug delivery, and therapy.

PH-sensitive linkers for delivering a therapeutic agent

Growing community of inventors

Taipei, Taiwan

Ye-Su Chao